Related Experiment Video

Updated: May 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Re: Understanding variation in primary prostate cancer treatment within the Veterans Health Administration

David F Penson

    The Journal of Urology
    |November 13, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
    07:34

    Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

    Published on: November 17, 2023

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
    13:19

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

    Published on: November 2, 2013

    Related Experiment Videos

    Last Updated: May 17, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
    07:34

    Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

    Published on: November 17, 2023

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
    13:19

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

    Published on: November 2, 2013

    Related Concept Videos

    Cancer Vaccines01:30

    Cancer Vaccines

    Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
    Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

    Cancer·2019

    Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.

    Cancer·2019

    Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes?

    The Journal of urology·2019

    Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

    Journal of managed care & specialty pharmacy·2019

    The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

    European urology·2019

    Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

    Journal of the National Comprehensive Cancer Network : JNCCN·2019

    Multicenter Randomized Controlled Trial Comparing Pulse-Modulated Holmium:YAG Laser and Thulium Fiber Laser in Retrograde Intrarenal Surgery for Dusting Kidney Stones.

    The Journal of urology·2026

    Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis.

    The Journal of urology·2026

    Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration.

    The Journal of urology·2026

    Age- and sex-specific prevalence of lower urinary tract symptoms and bowel dysfunction in children: Results from a National Survey.

    The Journal of urology·2026

    Therapeutic hybrid intelligence with neural and knowledge-based expert reasoning for SRS: an AI model for breast cancer brain metastases.

    Frontiers in oncology·2026

    Re-Examining the Applicability of the Linear No-Threshold (LNT) Theory in Radiation Protection for Very Low Doses: Does a Threshold Exist? The Carcinogenic Effect of Radiation and the Possibility of a Dose Threshold.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

    Comparative Physicochemical Characterization and Biological Effects of Magnetite- and Maghemite-Based Magnetic Colloidal Suspensions in A704 Renal Cancer Cells.

    Pharmaceuticals (Basel, Switzerland)·2026

    Drug Repurposing of Verapamil for Radiation-Induced Enteropathy: Regulation of 5-LOX, Nrf2, and Intestinal Barrier Function.

    Pharmaceuticals (Basel, Switzerland)·2026

    Reprogramming Photodynamic Therapy with BODIPY Photosensitizers: From Local Phototoxicity Toward Precision Photodynamic Oncology.

    Molecules (Basel, Switzerland)·2026

    Radiotherapy Modality and Primary Tumor Type as Determinants of Outcomes in Brain Metastases: A Retrospective Study of 734 Patients.

    Medicina (Kaunas, Lithuania)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us